Locus Cell Co Ltd 06891
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- TWD 32.40
- Day Range
- TWD 31.60–32.85
- 52-Week Range
- TWD 22.20–49.15
- Bid/Ask
- TWD 31.90 / TWD 32.15
- Market Cap
- TWD 6.43 Bil
- Volume/Avg
- 535,434 / 538,892
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Locus Cell Co Ltd focuses on contract development and manufacturing services for cell therapy-related products.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 22
- Website
- http://www.locus-cell.com
Comparables
Valuation
|
Metric
|
06891
|
6183
|
6937
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 23.35 | 42.43 |
Price/Book Value | 3.51 | 4.29 | 4.63 |
Price/Sales | — | 4.87 | 6.59 |
Price/Cash Flow | — | 18.09 | 32.53 |
Price/Earnings
06891
6183
6937
Financial Strength
|
Metric
|
06891
|
6183
|
6937
|
|---|---|---|---|
Quick Ratio | 63.77 | 2.40 | 2.86 |
Current Ratio | 64.05 | 2.47 | 4.94 |
Interest Coverage | −102.74 | 694.46 | 43.74 |
Quick Ratio
06891
6183
6937
Profitability
|
Metric
|
06891
|
6183
|
6937
|
|---|---|---|---|
Return on Assets (Normalized) | −4.48% | 13.71% | 9.65% |
Return on Equity (Normalized) | −4.68% | 19.04% | 14.09% |
Return on Invested Capital (Normalized) | −6.29% | 18.14% | 11.75% |
Return on Assets
06891
6183
6937
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Mngtqvxx | Vwfm | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Cbdhdslk | Npxyshm | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Fvhwnwkln | Bhdnbp | $97.8 Bil | |
MRNA
| Moderna Inc | Ynntmsrbp | Qrtm | $41.3 Bil | |
ARGX
| argenx SE ADR | Dbnbzkcsg | Knmj | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Rxxrfhkv | Mxzn | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Mklnzbmm | Tltbzs | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Pcxnysd | Ylgqw | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Kdvxywshw | Xxbbwx | $12.5 Bil | |
INCY
| Incyte Corp | Ffgyxlzg | Cxvpdd | $11.6 Bil |